FDA grants accelerated approval to new treatment for advanced ovarian cancer – FDA.gov
NBCNews.com |
FDA grants accelerated approval to new treatment for advanced ovarian cancer
FDA.gov The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more … FDA Approves Rucaparib for BRCA Ovarian Cancer PARP Inhibitor Gets FDA Nod for Ovarian Cancer Surprise! Clovis Oncology Nabs Early OK |
View original article
Author:
Powered by WPeMatico